EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas

Marco Minneci, Barbara Farkaš, Adeyemi Rahman, Amy Kempf, Inga Nehlmeier, Stefan Pöhlmann, Isabel Rozas iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202501000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Marco Minneci und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Trinity College Dublin, The University of Dublin, TBSI, Dublin, D02R590, Ireland. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Thiourea, SARS-CoV-2. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland/Enterprise Ireland/Industrial Development Agency COVID-19 Rapid Response Funding Call, Science Foundation Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic highlighted the urgent need for effective antiviral treatments targeting SARS‐CoV‐2. TMPRSS2, a serine protease essential for viral entry into host cells, represents a promising therapeutic target, and this study explores guanidino diaryl thioureas as potential TMPRSS2 inhibitors. Initial screening identified a “hit‐compound” ( 1 ) with reversible inhibitory activity against TMPRSS2. Computational studies, including docking and molecular dynamics simulations, were conducted to optimize derivatives of compound 1 . Twenty‐five derivatives were synthesized, and their pharmacokinetic properties and cytotoxicity assessments indicated favorable drug‐likeness and minimal toxicity. However, biochemical studies revealed that none of the derivatives improved TMPRSS2 inhibitory activity compared to the original “hit‐compound”. The findings suggest that reversible inhibitors may be suboptimal for TMPRSS2 targeting, as camostat and nafamostat exert their effects through irreversible covalent binding. Future efforts should focus on developing irreversible TMPRSS2 inhibitors to enhance antiviral efficacy against SARS‐CoV‐2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentThioureaSARS-CoV-2GuanidinesSerine Proteinase InhibitorsHumansSerine EndopeptidasesMolecular Docking SimulationStructure-Activity RelationshipMolecular Dynamics SimulationCOVID-19Animals

Stichwörter der Autor:innen

SARS‐CoV‐2TMPRSS2TMPRSS2 inhibitordockingguanidino diaryl N,N′‐thioureas

Substanzen

Antiviral AgentsThioureaTMPRSS2 protein, humanSerine EndopeptidasesGuanidinesSerine Proteinase Inhibitors

Autor:innen und Institutionen

  • School of Chemistry, Trinity College Dublin, The University of Dublin, TBSI, Dublin, D02R590, Ireland.
  • Infection Biology Unit, German Primate Center, 37077, Göttingen, Germany.

ORCID-Profile: Isabel Rozas

Förderung

  • Science Foundation Ireland/Enterprise Ireland/Industrial Development Agency COVID-19 Rapid Response Funding Call
  • Science Foundation Ireland

Zitieren

APA

Minneci, M., Farkaš, B., Rahman, A., Kempf, A., Nehlmeier, I., Pöhlmann, S., & Rozas, I. (2026). Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. ChemMedChem. https://doi.org/10.1002/cmdc.202501000

Vancouver

Minneci M, Farkaš B, Rahman A, Kempf A, Nehlmeier I, Pöhlmann S, et al. Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. ChemMedChem. 2026. doi:10.1002/cmdc.202501000

BibTeX
@article{Minneci2026,
  author = {Minneci, Marco and Farkaš, Barbara and Rahman, Adeyemi and Kempf, Amy and Nehlmeier, Inga and Pöhlmann, Stefan and Rozas, Isabel},
  title = {Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202501000}
}
Kostenlos starten →